Sun Pharmaceutical Industries Limited — Investor Meet, 11-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Sun Pharma delivered strong Q2 FY26 results with sales at ₹14,405 Cr (+8.6% YoY) and EBITDA at ₹4,527 Cr (+14.9%, 31.3% margin). Global Innovative Medicines sales surged 16.4% to $313M, now exceeding generics in the US. India formulations grew 11% to ₹4,734 Cr, maintaining #1 market share. US business saw a 4.1% decline due to generic competition, but innovative brands like ILUMYA, LEQSELVI, CEQUA, and ODOMZO are growing. R&D spend is ₹782 Cr (5.4% of sales), with UNLOXCYT and ILUMYA sBLA launches expected. The company remains focused on its innovative pipeline and market leadership.